AP3069A - Thienopyridine derivatives for the treatment and prvention of dengue virus infection - Google Patents

Thienopyridine derivatives for the treatment and prvention of dengue virus infection

Info

Publication number
AP3069A
AP3069A AP2011005901A AP2011005901A AP3069A AP 3069 A AP3069 A AP 3069A AP 2011005901 A AP2011005901 A AP 2011005901A AP 2011005901 A AP2011005901 A AP 2011005901A AP 3069 A AP3069 A AP 3069A
Authority
AP
ARIPO
Prior art keywords
prvention
treatment
virus infection
dengue virus
thienopyridine derivatives
Prior art date
Application number
AP2011005901A
Other languages
English (en)
Other versions
AP2011005901A0 (en
Inventor
Chelsea M Byrd
Dongcheng Dai
Robert Jordan
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of AP2011005901A0 publication Critical patent/AP2011005901A0/xx
Application granted granted Critical
Publication of AP3069A publication Critical patent/AP3069A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AP2011005901A 2009-02-27 2010-02-24 Thienopyridine derivatives for the treatment and prvention of dengue virus infection AP3069A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15613209P 2009-02-27 2009-02-27
PCT/US2010/025183 WO2010099166A1 (en) 2009-02-27 2010-02-24 Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Publications (2)

Publication Number Publication Date
AP2011005901A0 AP2011005901A0 (en) 2011-10-31
AP3069A true AP3069A (en) 2014-12-31

Family

ID=42665870

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005901A AP3069A (en) 2009-02-27 2010-02-24 Thienopyridine derivatives for the treatment and prvention of dengue virus infection

Country Status (12)

Country Link
US (2) US9301949B2 (xx)
EP (2) EP3181568A1 (xx)
JP (3) JP5854841B2 (xx)
KR (1) KR20110136819A (xx)
CN (2) CN104856991A (xx)
AP (1) AP3069A (xx)
AU (1) AU2010218152B2 (xx)
BR (1) BRPI1005828A2 (xx)
CA (1) CA2753421A1 (xx)
IL (1) IL214825A0 (xx)
MX (1) MX2011008988A (xx)
WO (1) WO2010099166A1 (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099166A1 (en) * 2009-02-27 2010-09-02 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections
JP6042331B2 (ja) 2010-07-23 2016-12-14 プレジデント アンド フェローズ オブ ハーバード カレッジ プロテアソーム活性を向上させる三環系化合物
NZ609564A (en) 2010-10-26 2015-06-26 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
JP2014528412A (ja) * 2011-09-30 2014-10-27 キネタ・インコーポレイテツド 抗ウイルス化合物
WO2013112706A1 (en) 2012-01-25 2013-08-01 Proteostasis Therapeutics, Inc. Proteasome activity modulating compounds
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
CA2881351A1 (en) 2012-09-07 2014-03-13 Novartis Ag Indole carboxamide derivatives and uses thereof
US10471082B2 (en) 2012-10-23 2019-11-12 Georgetown University Flavivirus protease inhibitors
JP2016501883A (ja) * 2012-12-07 2016-01-21 シガ テクノロジーズ，インコーポレーテッド デングウイルス感染症の治療及び予防のためのチエノピリジン誘導体
US9073946B2 (en) * 2013-01-15 2015-07-07 Kineta, Inc. Anti-viral compounds
US20160074373A1 (en) * 2013-01-23 2016-03-17 The University Of Chicago Methods and compositions for inhibiting human copper trafficking proteins atox1 and ccs
CN105418635A (zh) * 2015-12-25 2016-03-23 上海应用技术学院 一种噻吩并吡啶类医药中间体的合成方法
EP3414252B1 (en) * 2016-02-12 2022-07-06 Valo Health, Inc. Thienopyridine carboxamides as ubiquitin-specific protease inhibitors
ES2763274T3 (es) 2016-02-12 2020-05-27 Forma Therapeutics Inc Carboxamidas de tienopirazina como inhibidores de la proteasa específica de la ubiquitina
CN105832734B (zh) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 一种化合物在增加血小板浓度药物中的用途
CN105769866B (zh) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 一种化合物在增加血小板浓度药物中的用途
US10689394B2 (en) 2016-06-14 2020-06-23 The University Of Tokyo Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof
MX2019012257A (es) 2017-04-26 2019-12-16 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
AU2018316254B2 (en) 2017-08-11 2022-07-14 Valo Health, Inc. Carboxamides as ubiquitin-specific protease inhibitors
EP3704126A4 (en) 2017-11-03 2020-12-09 Université de Montréal COMPOUNDS AND THEIR USE IN THE EXPANSION OF STEM CELLS AND / OR PROGENITOR CELLS
CN108178764A (zh) * 2018-01-09 2018-06-19 天津科技大学 呋喃并[2,3-b]吡啶类化合物及无金属催化的合成方法
CN111920811B (zh) * 2018-06-13 2021-09-21 四川轻化工大学 一种治疗抗痛风、抗高尿酸血症的药物组合物ⅲ
CR20200618A (es) * 2018-06-19 2021-01-21 Novartis Ag Derivados de tetrahidrotienopiridina n-sustituidos y sus usos
CN109705136B (zh) * 2018-12-10 2020-08-21 济南大学 乙酰胆碱酯酶抑制剂及其应用
WO2020236688A1 (en) * 2019-05-22 2020-11-26 Merck Sharp & Dohme Corp. Natriuretic peptide receptor a agonists useful for the treatment of cardiometabolic diseases, kidney disease and diabetes
AU2021326457A1 (en) * 2020-08-10 2023-03-16 Dana-Farber Cancer Institute, Inc. Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
US20240139209A1 (en) * 2021-02-17 2024-05-02 Seoul National University R&Db Foundation Pharmaceutical composition for preventing or treating dengue fever

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20060019976A1 (en) * 2004-07-22 2006-01-26 Karp Gary M Methods for treating Hepatitis C
US20090047246A1 (en) * 2007-02-12 2009-02-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
WO1996009296A1 (fr) 1994-09-22 1996-03-28 Rational Drug Design Laboratories Derive d'arylthiadiazole et agent antiviral le contenant
DK1159279T3 (da) 1999-03-09 2003-02-17 Upjohn Co 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
CA2377649C (en) 2002-03-20 2009-02-03 Ibm Canada Limited-Ibm Canada Limitee Dynamic cluster database architecture
CA2514466C (en) 2003-02-19 2015-05-26 Yale University Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
GB0323810D0 (en) * 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
WO2005058315A1 (en) 2003-12-12 2005-06-30 Ribapharm, Inc. Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
US7875604B2 (en) * 2004-02-04 2011-01-25 University Of Virginia Patent Foundation Compounds that inhibit HIV particle formation
WO2006010567A1 (de) * 2004-07-23 2006-02-02 Curacyte Discovery Gmbh INHIBITOREN DER PHOSPHODIESTERASE 4 UND TNFα-FREISETZUNG
SE0403171D0 (sv) 2004-12-23 2004-12-23 Astrazeneca Ab New compounds
US7465742B2 (en) 2005-02-11 2008-12-16 Huanming Chen Heterocyclic compounds having anti-HBV activity
DE102005009440A1 (de) 2005-03-02 2006-09-07 Merck Patent Gmbh Thienopyridinderivate
JP2006298909A (ja) 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd 医薬組成物
CA2603322C (en) 2005-03-31 2014-12-16 Janssen Pharmaceutica N.V. Bicyclic pyrazole compounds as antibacterial agents
ES2389964T3 (es) 2005-07-29 2012-11-05 Janssen R&D Ireland Inhibidores macrocíclicos del virus de la hepatitis C
EA013475B1 (ru) 2005-07-29 2010-04-30 Тиботек Фармасьютикалз Лтд. Макроциклические ингибиторы вируса гепатита с
DE102006013957A1 (de) 2006-03-27 2007-10-04 Bayer Healthcare Aktiengesellschaft Substituierte N-Benzyl-N-phenylbenzolsulfonamide
EP2018384A2 (en) 2006-05-17 2009-01-28 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Pyrimidine low molecular weight ligands for modulating hormone receptors
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US20130129677A1 (en) 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
WO2010099166A1 (en) 2009-02-27 2010-09-02 Siga Technologies, Inc. Thienopyridine derivatives for the treatment and prevention of dengue virus infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20060019976A1 (en) * 2004-07-22 2006-01-26 Karp Gary M Methods for treating Hepatitis C
US20090047246A1 (en) * 2007-02-12 2009-02-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication

Also Published As

Publication number Publication date
JP2016145226A (ja) 2016-08-12
IL214825A0 (en) 2011-11-30
KR20110136819A (ko) 2011-12-21
BRPI1005828A2 (pt) 2017-07-18
US20160152635A1 (en) 2016-06-02
MX2011008988A (es) 2011-12-16
CN102395273A (zh) 2012-03-28
AU2010218152B2 (en) 2015-04-09
AP2011005901A0 (en) 2011-10-31
US20120022046A1 (en) 2012-01-26
JP2012519174A (ja) 2012-08-23
JP5956490B2 (ja) 2016-07-27
AU2010218152A1 (en) 2011-09-08
EP2400845B1 (en) 2017-02-22
EP3181568A1 (en) 2017-06-21
JP5854841B2 (ja) 2016-02-09
CN102395273B (zh) 2015-05-20
US9301949B2 (en) 2016-04-05
JP2014141506A (ja) 2014-08-07
EP2400845A1 (en) 2012-01-04
CN104856991A (zh) 2015-08-26
CA2753421A1 (en) 2010-09-02
WO2010099166A1 (en) 2010-09-02
EP2400845A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
AP3069A (en) Thienopyridine derivatives for the treatment and prvention of dengue virus infection
ZA201109187B (en) Treatment and prevention of dengue virus infections
FI3494972T3 (fi) Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon
EP2491033A4 (en) AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
GB2548034B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
ZA201105343B (en) Cyclosporine derivative for use in the treatment of hcv and hiv infection
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
ZA201303610B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
EP2427061A4 (en) GALLIUM FORMULATION FOR THE TREATMENT AND PROPHYLAXIS OF INFECTION DISEASES
GB0718446D0 (en) Compositions and methods for the treatment of infection
EP2651439A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION
EP2521554A4 (en) SUBSTANCES AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS
EP2928470A4 (en) THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS
EP2398321A4 (en) IMINOSUCKS AND METHODS FOR TREATING VIRAL DISEASES
HK1170733A1 (en) Thioxanthene derivatives for the treatment of infectious diseases
EP2403507A4 (en) TREATMENT OF INFECTIONS
EP2650292A4 (en) THIAZOLAMINE DERIVATIVE AND ITS PHARMACEUTICAL APPLICATIONS FOR SMALL RNA VIRAL INFECTIONS
GB0815179D0 (en) Medication and treatment for infection
HK1174256A1 (en) Treatment and prevention of hiv infection hiv
GB0813716D0 (en) Treatment of viral infection
GB0915434D0 (en) Treatment of hepatitis C
HK1141664A2 (en) Composition for the treatment of infection with human influenza viruses
AU2009900969A0 (en) Treatment of infection
GB0919711D0 (en) Treatment of viral infections
GB0913914D0 (en) Treatment of viral infections